PRME compared with ABSI: revenue, margins and what each company keeps, and the suppliers and customers both name

PRMEPrime Medicine, Inc.

Mkt capRevenueRevenue

ABSIAbsci Corp

Mkt capRevenueRevenue

Compare

PRMEPrime Medicine, Inc.

ABSIAbsci Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PRME

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.2%▼−4.22%×0.30

May 7 '26±15.5%▼−8.65%×0.56

Q1 FY26±18.4%▼−9.23%×0.50

Q3 FY25±17.6%▼−8.85%×0.50

ABSI

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.9%▲+0.96%×0.07

May 8 '26±14.2%▲+2.61%×0.18

= impliedPRME realized, solidABSI realized, hatchedOne scale, both sides: full bar = 23%× = |realized| ÷ impliedSource: market data

Q1 FY26

±19.5%

▼−2.99%

×0.15

Q3 FY25±13.8%▼−22.35%×1.62

PRMEPrime Medicine, Inc.

4.72▼−9.92%· post 4.71

Mkt cap—Revenue$1MQ2 FY26Revenue$5MFY25

ABSIAbsci Corp

11.12▼−8.10%· post 11.21

ClosedOct 30 '26

Mkt cap$1.9BRevenue$650,000Q4 FY25Revenue$3MFY25

Compare

ClosedOct 30 '26

PRMEPrime Medicine, Inc.

ABSIAbsci Corp

4.72▼−9.92%post 4.71

Price

11.12▼−8.10%post 11.21

—

Mkt cap

$1.9B

Q2 FY26$1M

Revenue

$650,000Q4 FY25

FY25$5M

Revenue

$3MFY25

PRME4.72▼−9.92%vsABSI11.12▼−8.10%ClosedOct 30 '26